Trials / Completed
CompletedNCT03038022
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- Madrigal Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in participants with Heterozygous Familial Hypercholesterolemia (HeFH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MGL-3196 (resmetirom) | Oral |
| DRUG | Placebo | Oral |
Timeline
- Start date
- 2017-02-23
- Primary completion
- 2018-01-15
- Completion
- 2018-01-15
- First posted
- 2017-01-31
- Last updated
- 2025-12-23
- Results posted
- 2025-12-23
Locations
13 sites across 3 countries: Denmark, Netherlands, Norway
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03038022. Inclusion in this directory is not an endorsement.